Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) have received an average rating of "Moderate Buy" from the eight analysts that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $20.00.

ANRO has been the topic of several analyst reports. Wedbush lowered Alto Neuroscience from an "outperform" rating to a "neutral" rating and reduced their price target for the stock from $29.00 to $4.00 in a report on Wednesday, October 23rd. RODMAN&RENSHAW downgraded shares of Alto Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 23rd. Robert W. Baird decreased their price objective on Alto Neuroscience from $32.00 to $10.00 and set an "outperform" rating on the stock in a report on Wednesday, October 23rd. Rodman & Renshaw lowered shares of Alto Neuroscience from a "buy" rating to a "neutral" rating in a research note on Wednesday, October 23rd. Finally, William Blair reaffirmed an "outperform" rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th.

Alto Neuroscience Price Performance

ANRO traded up $0.17 on Tuesday, reaching $4.51. 195,931 shares of the company's stock were exchanged, compared to its average volume of 222,483. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. Alto Neuroscience has a twelve month low of $3.56 and a twelve month high of $24.00. The stock's fifty day moving average price is $4.15 and its 200-day moving average price is $9.12.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.67) by $0.05. On average, analysts anticipate that Alto Neuroscience will post -2.54 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANRO. FMR LLC increased its stake in Alto Neuroscience by 1.4% in the third quarter. FMR LLC now owns 2,363,056 shares of the company's stock valued at $27,033,000 after purchasing an additional 32,040 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Alto Neuroscience by 95.3% in the 3rd quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company's stock valued at $13,965,000 after buying an additional 595,673 shares during the last quarter. Jennison Associates LLC raised its stake in Alto Neuroscience by 80.3% during the 3rd quarter. Jennison Associates LLC now owns 832,290 shares of the company's stock worth $9,521,000 after acquiring an additional 370,612 shares in the last quarter. Vestal Point Capital LP lifted its position in Alto Neuroscience by 4.8% in the third quarter. Vestal Point Capital LP now owns 650,000 shares of the company's stock valued at $7,436,000 after acquiring an additional 30,000 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Alto Neuroscience by 148.7% in the third quarter. Geode Capital Management LLC now owns 469,988 shares of the company's stock valued at $5,378,000 after acquiring an additional 281,018 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.